VivoSeq
Other

Maximum Tolerated Dose

0

Pipeline Programs↗

2

Active Trials↗

13

Companies Involved↗

Maximum Tolerated Dose is an early-stage landscape with 0 programs across 13 companies. The most active players are Bayer, INSYS Therapeutics Inc, Boehringer Ingelheim.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

76/100

Attrition Rate

22/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bayer logo

Bayer

0 programs

PreclinicalI

INSYS Therapeutics Inc

0 programs

PreclinicalBoehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalC

CrystalGenomics, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

32

clinical trials

Completed22 · 69%
Terminated6 · 19%
Withdrawn1 · 3%
Recruiting1 · 3%
Unknown status1 · 3%
Active, not recruiting1 · 3%

Clinical Trials

Trial Activity

32 trials

Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors
Recruiting·CCosmo Technologies Ltd·Phase 1·NCT03863145·90 enrolled
To Determine the Maximum Tolerated Dose (MTD) of HK-001 in Healthy Volunteers
Active, not recruiting·EEverfront Biotech Co., Ltd.·Phase 1·NCT03651349·56 enrolled
Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015)
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT00288431·37 enrolled
Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Cancer
Completed·IINSYS Therapeutics Inc·Phase 1·NCT00100672·40 enrolled
Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients
Completed·Novartis logoNovartis·Phase 1·NCT02988440·20 enrolled
Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel
Completed·PPeplin·Phase 2·NCT00239135·34 enrolled
To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC
Completed·PPeplin·Phase 2·NCT00432185·117 enrolled
A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)
Completed·HHiberCell, Inc.·Phase 1·NCT04834778·23 enrolled
A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder
Completed·IIndivior Inc.·Phase 2·NCT02511886·18 enrolled
A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.
Completed·NNewron Pharmaceuticals SPA·Phase 1·NCT01955564·54 enrolled
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies
Completed·Bayer logoBayer·Phase 1·NCT01188252·112 enrolled
Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)
Completed·Bayer logoBayer·Phase 1·NCT00941863·158 enrolled
Study to Determine Maximum Tolerated Dose of LErafAON Combined With Radiotherapy in Patients With Advanced Malignancies
Completed·IINSYS Therapeutics Inc·Phase 1·NCT00024648·25 enrolled
A Phase I Maximum Tolerated Dose Study of CI-1012 in Late-Stage HIV+ Patients
Completed·PParke-Davis·Phase 1·NCT00002218·40 enrolled
Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies
Completed·Bayer logoBayer·Phase 1·NCT01335256·10 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)